Radioimmunotherapy with 131I-bevacizumab as a specific molecule for cells with overexpression of the vascular endothelial growth factor

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 7, 2012, Pages 420-425

  Ashrafi, Saeb Ahmad ^a   Hosseinimehr, Seyed Jalal ^a   Varmira, Kambiz ^a   Abedi, Seyed Mohammad ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

131I; Bevacizumab; radioimmunotherapyvascular endothelial growth factor

Indexed keywords

BEVACIZUMAB I 131; RADIOPHARMACEUTICAL AGENT; TOSYLCHLORAMIDE SODIUM; UNCLASSIFIED DRUG; VASCULOTROPIN; BEVACIZUMAB; IMMUNOTOXIN; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL SPECIFICITY; CELL VIABILITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG PURITY; DRUG STABILITY; FEMALE; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MALE; MOUSE; NONHUMAN; OVARY CANCER; PLASMA CLEARANCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION; SALIVARY GLAND; THIN LAYER CHROMATOGRAPHY; TUMOR CELL; ANIMAL; BIOSYNTHESIS; CHEMISTRY; IMMUNOLOGY; METABOLISM; METHODOLOGY; OVARY TUMOR; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTOXINS; IODINE RADIOISOTOPES; MALE; MICE; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866302813     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1224     Document Type: Article

References (27)

1. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488.
2. Dixon KL. The radiation biology of radioimmunotherapy. Nucl Med Commun. 2003;24:951.
3. Postema EJ, Boerman OC, Oyen WJ, et al. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur J Nucl Med 2001;28:1725.
4. Nordoy T, Kolstad A, Tuck MK, et al. Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens. Clin Immunol 2001;100:40.
5. Giammarile F, Chiti A, Lassmann M, et al. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 2008;35:1039.
6. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984;11:638.
7. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986;27:1490.
8. Iagaru A, Mittra ES, Ganjoo K, et al. 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of lowgrade refractory/relapsed non-Hodgkin lymphoma. Mol Imaging Biol 2010;12:198.
9. Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest oncology group protocol S9911. Blood 2003;102:1606.
10. Los M, Roodhart JM, Voest EE. Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007; 12:443.
11. Huusko J, Merentie M, Dijkstra MH, et al. The effects of VEGF-R1 and VEGF-R2 ligands on angiogenic responses and left ventricular function in mice. Cardiovasc Res 2010;86:122.
12. Croom K, Dhillon S. Bevacizumab: A review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 2011;71:2213.
13. Hosseinimehr SJ, Orlova A, Tolmachev V. Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab. Hum Antibodies 2010;19:107.
14. Paudyal B, Paudyal P, Oriuchi N, et al. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci 2011;102:117.
15. Rasaneh S, Rajabi H, Babaei MH, et al. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl Med Biol 2009;36:363.
16. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4:1317.
17. Hamilton EP, Blackwell KL. Safety of bevacizumab in patients with metastatic breast cancer. Oncology 2011;80:314.
18. Mulder K, Scarfe A, Chua N, et al. The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. Expert Opin Biol Ther 2011;11:405.
19. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593.
20. Mukherji SK. Bevacizumab (Avastin). AJNR Am J Neuroradiol 2010;31:235.
21. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007;48:1313.
22. Stollman TH, Scheer MG, Franssen GM, et al. Tumor accumulation of radiolabeled bevacizumab due to targeting of cell-and matrix-associated VEGF-A isoforms. Cancer Biother Radiopharm 2009;24:195.
23. Stollman TH, Scheer MG, Leenders WP, et al. Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer 2008;122:2310.
24. Desar IM, Stillebroer AB, Oosterwijk E, et al. 111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib. J Nucl Med 2010;51:1707.
25. Morgenroth A, Deisenhofer S, Neininger M, et al. Biodistribution, cellular uptake and DNA-incorporation of the 2¢-fluoro stabilized 5-iodo-2¢-deoxyuridine analog 5-iodo-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)uracil (FIAU). Q J Nucl Med Mol Imaging 2008;52:305.
26. Stewart RD, Yu VK, Georgakilas AG, et al. Effects of radiation quality and oxygen on clustered DNA lesions and cell death. Radiat Res 2011;176:587.
27. Stollman T, Ruers T, Oyen W, et al. New targeted probes for radioimaging of angiogenesis. Methods 2009;48:188.